1. Scrip
  2. >>Business
  3. >>Financing

Interview: AbiVax Equipped To Enter Anti-Inflammatory Market

 
• By Kevin Grogan

The French biotech's CEO tells Scrip the firm now has the time and resources to sign up a big pharma partner for its ulcerative colitis, RA and Crohn’s candidate.

Eiffel tower
Paris-based Abivax maps out its future • Source: Shutterstock

Boosted by a recent €12m cash injection from leading healthcare investor Sofinnova Partners, France's Abivax can now focus on steering its flagship anti-inflammatory ABX464 through three key mid-stage trials.

Sofinnova has bought 1.5 million new shares at the market price of €8 each to take a stake of around...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.